Literature DB >> 1379374

Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease.

G J Dover1, S Charache.   

Abstract

In the past 8 years, it has become apparent that some cytotoxic drugs that interfere with DNA replication can reprogram erythroid progenitors to switch from adult hemoglobin to fetal hemoglobin (HbF) production. Hydroxyurea has now been shown to substantially increase HbF in patients with sickle cell anemia. Since HbF interferes with sickle hemoglobin polymerization, hydroxyurea may become an important therapeutic agent for patients with sickle cell anemia.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1379374

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  4 in total

1.  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Authors:  Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw
Journal:  Pain Med       Date:  2011-04-11       Impact factor: 3.750

2.  Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro.

Authors:  D Roa; P Kopsombut; M P Aguinaga; E A Turner
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

3.  Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.

Authors:  R Borba; C S P Lima; H Z W Grotto
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

4.  Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.

Authors:  Rosario Di Maggio; Matthew M Hsieh; Xiongce Zhao; Giuseppina Calvaruso; Paolo Rigano; Disma Renda; John F Tisdale; Aurelio Maggio
Journal:  Int J Mol Sci       Date:  2018-02-28       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.